Boston biotech Atea Pharmaceuticals, a developer of small molecule drugs for infectious diseases, has raised $300 million in an initial public offering, selling 12.5 million shares at $24 apiece.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,